Results 51 to 60 of about 149,399 (260)
Molecular Oncology, EarlyView.Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary +1 more
wiley +1 more source
Molecular Oncology, EarlyView.This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska +13 more
wiley +1 more source
Molecular Oncology, EarlyView.We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober +16 more
wiley +1 more source
Advances in the innate immune evasion by Chlamydia trachomatis
Pifu-xingbing zhenliaoxue zazhiChlamydia trachomatis（Ct）is the pathogen responsible for the most common bacterial sexually transmitted disease. Its unique intracellular survival mode and complex immune evasion mechanisms enable it to establish long-term infections within the host ...
CHEN Yuzhen, XUE Yaohua, CHEN Wentao
doaj +1 more source
Molecular Oncology, EarlyView.The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka +9 more
wiley +1 more source
Immune Evasion of Enteroviruses Under Innate Immune Monitoring
Frontiers in Microbiology, 2018 As a major component of immunological defense against a great variety of pathogens, innate immunity is capable of activating the adaptive immune system.
Ying Zhang, Jingyan Li, Qihan Li
doaj +1 more source
Liquid biopsy‐based diagnostic evaluation of hypermethylated CpG sites for ovarian cancer diagnosis
Molecular Oncology, EarlyView.This schematic outlines the workflow from biomarker identification to duplex MethyLight assay validation for epithelial ovarian cancer diagnosis using cfDNA‐based liquid biopsy. Initial screening of hypermethylated CpG candidates (cg02957270, cg10061138 cg00480298, COL2A1) was performed in tissue using ARMS‐PCR, COBRA, qPCR and image analysis. Selected
Deepa Bisht +3 more
wiley +1 more source
Immune evasion of Pseudomonas aeruginosa
Japanese Journal of Clinical Immunology, 2014 Pseudomonas aeruginosa is an indigenous bacteria which inhabits on the surfaces of aqueous environments and is representative pathogen that causes opportunistic infection. P.aeruginosa is classified as low-virulence organism because it rarely causes infection in immunocompetent hosts, but in immunocompromised hosts it can cause a variety of severe ...
SHIMADA, Takahiro, MATSUMURA, Itaru
openaire +3 more sources
Complex pattern of immune evasion in MSI colorectal cancer
OncoImmunology, 2018 Mismatch repair (MMR)-deficient cancers accumulate multiple insertion/deletion mutations at coding microsatellites (cMS), which give rise to frameshift peptide neoantigens.
Mine Ozcan +3 more
doaj +1 more source
Molecular Oncology, EarlyView.Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim +3 more
wiley +1 more source